SER (Serina Therapeutics) Marketable Securities : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Serina Therapeutics's Marketable Securities for the quarter that ended in Mar. 2025 was $0.00 Mil.

Serina Therapeutics Marketable Securities Historical Data

The historical data trend for Serina Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Marketable Securities Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Marketable Securities

1.00

Serina Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial						-	-	-	-	-

Serina Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Serina Therapeutics (AMEX:SER) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Serina Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Executives

Stephen K. Brannan	director	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jay Venkatesan	director	C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gregory S Curhan	officer: Chief Financial Officer	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Srini Tenjarla	officer: SVP, CMC & Formulation	601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Simba Gill	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Tacey Viegas	officer: COO and Secretary	601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Randall Moreadith	officer: Chief Scientific Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Remy Gross	director	601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
J Milton Harris	director	C/O NEKTAR THERAPEUTIC, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Steven A Ledger	director, officer: Interim CEO	24 TAMALPAIS AVE, MILL VALLEY CA 94941
Richard Peter Marshall	director	601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Steven Mintz	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540